Download ESMO Preceptorship Lung Cancer Manchester 2017 Programme

esmo.org
PRECEPTORSHIP
PROGRAMME
Lung Cancer
Multidisciplinary management,
standards of care and future
perspectives
UNITED KINGDOM
MANCHESTER
1-3 MARCH 2017
Co-Chairs Fiona Blackhall, UK
Raffaele Califano, UK
Rolf A. Stahel, CH
ESMO-THE CHRISTIE
PRECEPTORSHIP PROGRAMME
LUNG CANCER
Multidisciplinary management, standards of care and future perspectives
Manchester, United Kingdom
1-3 March 2017
CO-CHAIRS:
SPEAKERS:
Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Rolf A. Stahel, Switzerland
Mo Al Aloul, United Kingdom
Neil Bayman, United Kingdom
Haval Balata, United Kingdom
Richard Booton, United Kingdom
Federico Cappuzzo, Italy
Clara Chan, United Kingdom
Richard Cowan, United Kingdom
Caroline Dive, United Kingdom
Jean-Yves Douillard, Switzerland
Corinne Faivre-Finn, United Kingdom
Enriqueta Felip, Spain
Martin Fruh, Switzerland
John Gosney, United Kingdom
Rohit Kochhar, United Kingdom
Jaroslaw Kuzdzal, Poland
Cecile Le Pechoux, France
Eric Lim, United Kingdom
Catherine McBain, United Kingdom
Silvia Novello, Italy
Laura Pemberton, United Kingdom
Solange Peters, Switzerland
Suresh Senan, Netherlands
Hamid Sheikh, United Kingdom
Yvonne Summers, United Kingdom
Florian Strasser, Switzerland
Paul Taylor, United Kingdom
Dominique Grunenwald, France
LEARNING OBJECTIVES
•
•
•
•
•
•
•
•
To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
To learn about the management of early stage NSCLC and use of adjuvant treatments
To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
To learn about treatment of NSCLC with oligometastatic disease
To learn about the systemic treatment of mesothelioma and small cell lung cancer
To learn about the role of supportive and palliative care for thoracic malignancies
ACCREDITATION
The programme of this event has been accredited with 16 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a
certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and
standards for the practice of medical oncology. For further details, please refer to esmo.org.
ACKNOWLEDGEMENTS
This event is supported by an unrestricted educational grant from
Wednesday,, 1 March 2017
08:15-09:15
60’
Registration
09:15-11:10
115’
SESSION 1
Screening and diagnostics for lung cancer
Chairs: Raffaele Califano, UK
John Gosney, UK
15’
Welcome from The Christie School of Oncology
Richard Cowan, UK
40’
Lung cancer screening: Pro and Contra
Haval Balata, UK
30’
EBUS TBNA in diagnosis/staging of lung cancer
Richard Booton, UK
30’
Role of pathologist in diagnosis and mutation analysis of lung cancer
John Gosney, UK (ESMO)
11:1011:10-11:30
Coffee Break
11:30-12:30
60’
SESSION 1
Screening and diagnostics for lung cancer - cont.
Chairs: Raffaele Califano, UK
John Gosney, UK
30’
PET/CT in staging of lung cancer
Rohit Kochhar, UK
30’
Medical thoracoscopy in the management of thoracic malignancies
Mo Al Aloul, UK
12:3012:30-13:20
Lunch
13:20-15:20
120’
SESSION 2
Radical treatment of early stage NSCLC
Chairs: Cecile Le Pechoux, FR
Dominique Grunenwald, FR
Dominique Grunenwald, FR (ESMO)
30’
Surgery for early stage NSCLC
30’
Stereotactic ablative RT for early stage NSCLC
Suresh Senan, NL (ESMO)
30’
Adjuvant radiotherapy for completely resected early stage NSCLC
Cecile Le Pechoux, FR (ESMO)
30’
Adjuvant chemotherapy for resected early stage NSCLC
Paul Taylor, UK
15:20
15:2015:40
:20-15:40
Coffee Break
15:40-15:50
10’
Close of day 1
(presentation not given, but slides available)
Chairmen
Thursday,, 2 March 2017
09:05-10:35
90’
SESSION 3
Advanced NSCLC
Chairs: Fiona Blackhall, UK
Jean-Yves Douillard, CH
30’
First-line chemotherapy for advanced NSCLC
Jean-Yves Douillard, CH (ESMO)
30’
Second-line treatment for advanced NSCLC
Silvia Novello, IT (ESMO)
30’
Treatment of EGFR mutant advanced NSCLC
Raffaele Califano, UK
10:3510:35-10:50
Coffee Break
10:50-12:40
110’
SESSION 3
Advanced NSCLC - cont.
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in
NSCLC
Chairs: Fiona Blackhall, UK
Jean-Yves Douillard, CH
30’
Treatment of ALK positive advanced NSCLC
Fiona Blackhall, UK
20’
Maintenance treatment for advanced NSCLC
Yvonne Summers, UK
30’
Immunotherapy for lung cancer
Solange Peters, CH (ESMO)
30’
12:4012:40-13:30
Lunch
Federico Cappuzzo, IT (ESMO)
13:30-15:00
90’
SESSION 4
Palliative treatment of lung cancer and mesothelioma
Chairs: Catherine McBain, UK
Rolf A. Stahel, CH
30’
Systemic treatment of mesothelioma
Rolf A. Stahel, CH (ESMO)
30’
Treatment of oligometastatic NSCLC
Jaroslaw Kuzdzal, PL (ESMO)
30’
Radical treatment of brain metastases: the importance of a neurooncology multi-disciplinary approach
Catherine McBain, UK
15:0015:00-15:20
Coffee Break
15:20-16:20
60’
SESSION 4
Palliative treatment of lung cancer and mesothelioma - cont.
Chairs: Raffaele Califano, UK
Florian Strasser, CH
30’
Supportive and palliative care in lung cancer
Florian Strasser, CH (ESMO)
30’
Intra-luminal radiotherapy
Hamid Sheikh, UK
16:20-16:30
10’
Close of day 2
Chairmen
18:30
18:30
Welcome Drink
19:00
19:00
Dinner
Friday,, 3 March 2017
09:05-10:35
90’
SESSION 5
Locally advanced NSCLC
Chairs: Eric Lim, UK
Corinne Faivre-Finn, UK
30’
Treatment of locally advanced NSCLC in the elderly
Laura Pemberton, UK
30’
Combined modality treatment for N2 disease
Clara Chan, UK
30’
Role of surgery for N2 disease
Eric Lim, UK (ESMO)
10:3510:35-11:00
Coffee Break
11:00-12:00
60’
SESSION 5
Locally advanced NSCLC - cont.
Chairs: Eric Lim, UK
Corinne Faivre-Finn, UK
3x20’
3 x Participant clinical case discussion
Faculty
Each 20 min slot for clinical case discussion includes 10’ case presentation and 10’ Q&A / interactive panel discussion
12:0012:00-12:50
Lunch
12:50-14:20
90’
SESSION 6
Small Cell Lung Cancer
Chairs: Enriqueta Felip, ES
Corinne Faivre-Finn, UK
30’
Treatment of limited stage SCLC
Corinne Faivre-Finn, UK
30’
Treatment of extensive stage SCLC
Martin Fruh, CH (ESMO)
30’
Targeted agents in SCLC
Enriqueta Felip, ES (ESMO)
14:2014:20-14:40
Coffee Break
14:40-15:40
60’
SESSION 6
Small Cell Lung Cancer - cont.
Prophylactic cranial irradiation and role of thoracic RT for extensive stage
SCLC
Versatility of circulating tumour cells in SCLC – biomarkers, biology,
mouse models and drug development
Neil Bayman, UK
Conclusion and farewell
Raffaele Califano, UK
30’
30’
15:40-15:50
10’
Chair:
Corinne Faivre-Finn, UK
Caroline Dive, UK